Myomo adds investor Joseph M. Manko to board

Myomo, Inc. appointed Joseph M. (Joe) Manko Jr. to its Board of Directors effective May 9, 2026.

Rhea-AI Filing Summary

Myomo, Inc. appointed Joseph M. (Joe) Manko Jr. to its Board of Directors effective May 9, 2026. He will serve as a Class I director until the 2027 annual meeting of stockholders, when he will be eligible for election by shareholders.

Manko, age 60, is Senior Principal of Horton Capital Management LLC, a significant Myomo shareholder, and brings more than 25 years of experience across investment banking, private equity, asset management and corporate strategy. With his appointment, Myomo’s Board now has seven directors.

He will receive the same compensation as other non-employee directors beginning after the 2026 annual meeting, currently an annual cash retainer of $60,000 and an annual grant of restricted stock units with a grant date fair value of $85,000. He has entered into a standard indemnification agreement with the company, and there are no related-party transactions requiring disclosure.

8-K Event Classification

3 items: 5.02, 7.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Board size after appointment: 7 directors Director annual cash retainer: $60,000 Director annual RSU grant value: $85,000 +2 more

5 metrics

Board size after appointment 7 directors Stated in press release following Manko’s appointment

Director annual cash retainer $60,000 Current compensation for non-employee directors who do not chair committees

Director annual RSU grant value $85,000 Grant date fair value of restricted stock units for non-employee directors

Effective date of appointment May 9, 2026 Start date of Joseph M. Manko Jr.’s service as director

Director age 60 years Age of Joseph M. Manko Jr. as disclosed

Key Terms

Emerging growth company, Regulation FD Disclosure, indemnification agreement, restricted stock units, +1 more

5 terms

Emerging growth company regulatory

"Emerging growth company Item 5.02 Departure of Directors or Certain Officers;"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Regulation FD Disclosure regulatory

"Item 7.01 Regulation FD Disclosure. On May 13, 2026, the Company issued a press release"

Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

indemnification agreement legal

"In addition, Mr. Manko has entered into an indemnification agreement with the Company"

An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.

restricted stock units financial

"an annual cash retainer of $60,000 and an annual grant of restricted stock units with a grant date fair value of $85,000"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

upper-limb orthosis technical

"MyoPro is a powered upper-limb orthosis designed to support the arm and restore function"

An upper-limb orthosis is a medical device—like a brace or supportive splint—designed to support, protect, align, or assist movement of the shoulder, arm, elbow, wrist or hand after injury, surgery, or because of neurological or musculoskeletal conditions. It matters to investors because these devices are regulated medical products with demand tied to clinical needs, reimbursement rules, and adoption by hospitals, clinics and patients, which influence manufacturers’ sales and growth prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Myomo (MYO) announce in this Form 8-K?

Myomo announced the appointment of Joseph M. Manko Jr. to its Board of Directors, effective May 9, 2026. He will serve as a Class I director until the 2027 annual meeting of stockholders.

Who is Joseph M. Manko Jr., the new Myomo (MYO) director?

Joseph M. Manko Jr. is Senior Principal of Horton Capital Management LLC, a significant Myomo shareholder. He has over 25 years of experience in investment banking, private equity, asset management and corporate strategy, and has served on multiple med-tech and biopharma boards.

How long will Joseph M. Manko Jr. serve on the Myomo (MYO) board?

Joseph M. Manko Jr. will serve as a Class I director until Myomo’s 2027 annual meeting of stockholders. At that meeting, he is expected to stand for election by shareholders to continue serving on the Board.

How will Myomo (MYO) compensate its new director Joseph M. Manko Jr.?

Beginning after the 2026 annual meeting, Manko will be compensated like other non-employee directors, with an annual cash retainer of $60,000 and an annual grant of restricted stock units valued at $85,000 on the grant date.

Does Joseph M. Manko Jr. have related-party transactions with Myomo (MYO)?

The company states that Manko is not a party to any transaction requiring disclosure as a related-party transaction. He has, however, entered into an indemnification agreement consistent with those for other non-employee directors.

How many directors does Myomo (MYO) have after this appointment?

After appointing Joseph M. Manko Jr., Myomo’s Board of Directors consists of seven members. The company highlighted his capital markets and governance experience as a complement to the existing board composition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/13/2026 - 04:10 PM Learn about SEC filing dates

0001369290false00013692902026-05-092026-05-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 09, 2026

MYOMO, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-38109	47-0944526
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
45 Blue Sky Dr. Suite 101
Burlington, Massachusetts				01803
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 617 996-9058

,

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		MYO		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 9, 2026, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Myomo, Inc. (the "Company"), the Board appointed Joseph M. Manko Jr. to join the Board, effective on May 9, 2026. Mr. Manko will serve as a Class I director until his term expires at the 2027 annual meeting of shareholders, at which time he will stand for election by the Company’s shareholders. Mr. Manko has not been appointed to serve on any committees of the Board.

Mr. Manko, 60, is currently the Senior Principal of Horton Capital Management LLC (“Horton Fund”), which he founded in 2013 and is a significant shareholder in the Company. Previous to his experience with Horton Fund, Mr. Manko was a Partner and Chief Executive Officer of Switzerland-based BZ Fund Management Limited from 2005 to 2010, where he was responsible for corporate finance, private equity investments, three public equity funds and the firm’s Special Situations and Event-Driven strategies. Prior to that Mr. Manko was a Managing Director with Deutsche Bank in London. He began his investment banking career at Merrill Lynch as a Vice President in Hong Kong and prior to that, Mr. Manko was a corporate finance attorney at Skadden, Arps, Slate, Meagher & Flom LLP. Mr. Manko has served on the boards of several companies in the med-tech and bio-pharmaceutical industry and has advised numerous companies in the pharmaceutical, biotech and medtech industries. He currently serves as a director and Chairman of Safeguard Scientifics, Inc. and director of KORU Medical Systems, Inc. Mr. Manko earned both his B.A. and Juris Doctor from the University of Pennsylvania.

Mr. Manko is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Mr. Manko and any other persons pursuant to which he was selected as a director. In addition, Mr. Manko has entered into an indemnification agreement with the Company consistent with the form of indemnification agreement entered into between the Company and its existing non-employee directors. Mr. Manko will be compensated in the same manner as other non-employee directors for his service on the Board beginning after the 2026 Annual Meeting of Stockholders. Current compensation for directors who do not chair committees is an annual cash retainer of $60,000 and an annual grant of restricted stock units with a grant date fair value of $85,000.

Item 7.01 Regulation FD Disclosure.

On May 13, 2026, the Company issued a press release announcing the appointment of Mr. Manko. A copy of the Company’s press release relating to this announcement is attached as Exhibit 99.1 to this current report on Form 8-K (the “Report”).

The information contained in Item 7.01 of this Report and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by Myomo, Inc. on May 13, 2026. furnished herewith.
104		The cover page from the Company’s Form 8-K dated May 13, 2026, formatted in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Myomo, Inc.
Date:	May 13, 2026	By:	/s/ David A. Henry
			David A. Henry Chief Financial Officer

Exhibit 99.1

Myomo Appoints Joseph M. Manko to its Board of Directors

BURLINGTON, MA. (May 13, 2026) - Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Joseph M. (“Joe”) Manko Jr. as a director effective May 9, 2026, to serve until the 2027 annual meeting of stockholders. With this appointment, Myomo has seven directors.

Mr. Manko is an accomplished investor with over 25 years of experience in investment banking, private equity, asset management and corporate strategy. Mr. Manko is currently the Senior Principal of Horton Capital Management LLC (“The Horton Fund”), a significant shareholder in the Company. Mr. Manko founded The Horton Fund in 2013.

“We are pleased to welcome Joe to our Board of Directors,” said Paul R. Gudonis, Chairman and Chief Executive Officer of Myomo. " Through The Horton Fund, Joe has long been a steadfast investor and supporter for years. He brings strong capital markets, strategic planning, and corporate governance experience to our Board, with a history of driving shareholder value in growth businesses. We are pleased to add his perspective as we execute on our Success Pillars for 2026 and beyond.”

Mr. Manko’s asset management and investment banking experience includes serving in executive positions at BZ Fund Management, Deutsche Bank and Merrill Lynch. He also served as a corporate finance attorney at Skadden, Arps, Slate, Meagher and Flom. Mr. Manko currently serves on the boards of Safeguard Scientifics and Koru Medical Systems, and previously served as a director on the boards of One Stop Systems, Creative Realties and Wireless Telecom Group. Mr. Manko earned both his B.A. and Juris Doctor from the University of Pennsylvania.

“I am excited to join the Myomo Board of Directors at such an important time in the Company’s development,” said Mr. Manko. “Myomo has built an innovative technology platform that is making a meaningful impact on patients’ lives, while addressing a significant unmet need. I look forward to working closely with management and my fellow directors to help support the Company’s growth strategy, expand patient access, and drive long-term value for shareholders.”

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Burlington, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com

Contacts:

Myomo

Myomo Inc. | 45 Blue Sky Dr., Suite 101 | Burlington, MA 01803

TEL: 877.736.9666 www.myomo.com info@myomo.com

ir@myomo.com

Alliance Advisors IR

Bruce Voss

bvoss@allianceadvisors.com

212-201-6614

# # #

Myomo Inc. | 45 Blue Sky Dr., Suite 101 | Burlington, MA 01803

TEL: 877.736.9666 www.myomo.com info@myomo.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 16.5 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 24.2 KB